Rexlemestrocel-L + Rexlemestrocel-L + HA Mixture + Placebo
Phase 3Completed 0 watching 0 views this week๐ Rising
72
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Degenerative Disc Disease
Conditions
Degenerative Disc Disease
Trial Timeline
Mar 6, 2015 โ Jun 15, 2021
NCT ID
NCT02412735About Rexlemestrocel-L + Rexlemestrocel-L + HA Mixture + Placebo
Rexlemestrocel-L + Rexlemestrocel-L + HA Mixture + Placebo is a phase 3 stage product being developed by Mesoblast for Degenerative Disc Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02412735. Target conditions include Degenerative Disc Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02412735 | Phase 3 | Completed |
Competing Products
17 competing products in Degenerative Disc Disease